Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/175824
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Castells, Aina-Alba | - |
dc.contributor.author | Balada, Rafel | - |
dc.contributor.author | Tristán Noguero, Alba | - |
dc.contributor.author | O’Callaghan, Mar | - |
dc.contributor.author | Cortès i Saladelafont, Elisenda | - |
dc.contributor.author | Pascual Alonso, Ainhoa | - |
dc.contributor.author | Garcia Cazorla, Àngels | - |
dc.contributor.author | Armstrong, Judith | - |
dc.contributor.author | Alcántara Horrillo, Soledad | - |
dc.date.accessioned | 2021-03-26T09:56:24Z | - |
dc.date.available | 2021-03-26T09:56:24Z | - |
dc.date.issued | 2021-02-03 | - |
dc.identifier.uri | http://hdl.handle.net/2445/175824 | - |
dc.description.abstract | Methyl-CpG-binding protein 2 (MeCP2) is an X-linked epigenetic modulator whose dosage is critical for neural development and function. Loss-of-function mutations in MECP2 cause Rett Syndrome (RTT, OMIM #312750) while duplications in the Xq28 locus containing MECP2 and Interleukin-1 receptor-associated kinase 1 (IRAK1) cause MECP2 duplication syndrome (MDS, OMIM #300260). Both are rare neurodevelopmental disorders that share clinical symptoms, including intellectual disability, loss of speech, hand stereotypies, vasomotor deficits and seizures. The main objective of this exploratory study is to identify novel signaling pathways and potential quantitative biomarkers that could aid early diagnosis and/or the monitoring of disease progression in clinical trials. We analyzed by RT-PCR gene expression in whole blood and microRNA (miRNA) expression in plasma, in a cohort of 20 females with Rett syndrome, 2 males with MECP2 duplication syndrome and 28 healthy controls, and correlated RNA expression with disease and clinical parameters. We have identified a set of potential biomarker panels for RTT diagnostic and disease stratification of patients with microcephaly and vasomotor deficits. Our study sets the basis for larger studies leading to the identification of specific miRNA signatures for early RTT detection, stratification, disease progression and segregation from other neurodevelopmental disorders. Nevertheless, these data will require verification and validation in further studies with larger sample size including a whole range of ages. | - |
dc.format.extent | 22 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | MDPI | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3390/biomedicines9020148 | - |
dc.relation.ispartof | Biomedicines, 2021, vol. 9, num. 2 | - |
dc.relation.uri | https://doi.org/10.3390/biomedicines9020148 | - |
dc.rights | cc by (c) Castells et al., 2021 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Patologia i Terapèutica Experimental) | - |
dc.subject.classification | Síndrome de Rett | - |
dc.subject.classification | Marcadors bioquímics | - |
dc.subject.other | Rett syndrome | - |
dc.subject.other | Biochemical markers | - |
dc.title | Unraveling Molecular Pathways Altered in MeCP2-Related Syndromes, in the Search for New Potential Avenues for Therapy | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2021-03-23T14:57:10Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 33546327 | - |
Appears in Collections: | Articles publicats en revistes (Patologia i Terapèutica Experimental) Articles publicats en revistes (Institut de Neurociències (UBNeuro)) Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
biomedicines-09-00148-v3 (1).pdf | 2.16 MB | Adobe PDF | View/Open |
This item is licensed under a
Creative Commons License